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Abstract
Background: Unlike other cardiovascular diseases the incidence and prevalence of congestive
heart failure (CHF) continues to increase. While gender differences in coronary artery disease have
been well described, to date, there has been a relative paucity of similar data in patients with CHF.
We conducted a pilot study to evaluate the profile and management of patients with CHF at a
tertiary care centre to determine if a gender difference exists.
Methods:  A chart review was performed at a tertiary care centre on consecutive patients
admitted with a primary diagnosis of CHF between June 1997 and 1998. Co-morbidity, diagnostic
investigations, and management of CHF were recorded. Comparisons between male and female
patients were conducted.
Results: One hundred and forty five patients were reviewed. There were 80 male (M) and 65
female (F) patients of similar age [71.6 vs. 71.3 (M vs. F), p = NS]. Male patients were more likely
to have had a previous myocardial infarction (66% vs. 35%, p < 0.01) and revascularization (41% vs.
20%, p < 0.05), and had worse left ventricular ejection fraction (LVEF) than women, [median LVEF
3 vs. 2 (M vs. F), p < 0.01]. Male patients were more likely to have a non-invasive assessment of left
ventricular (LV) function [85% vs. 69%, (M vs. F), p < 0.05]. A logistic regression analysis suggests
that amongst those without coronary disease, males were more likely to receive non-invasive
testing. There were no differences in the use of prescribed medications, in this cohort.
Conclusions: This pilot study demonstrated that there seem to be important gender differences
in the profile and management of patients with CHF. Importantly women were less likely to have
an evaluation of LV function. As assessment of LV function has significant implications on patient
management, this data justifies the need for larger studies to assess gender differences in CHF
profile and treatment.
Background
Congestive heart failure (CHF), a common medical con-
dition associated with high mortality and morbidity, has
an enormous impact on public health. [1–6] In Canada,
as in the United States, CHF is the leading cause of hospi-
talisation in the elderly. In the province of Ontario alone,
there are approximately 13,000 admissions annually for
CHF. One-year case fatality for patients with CHF in On-
tario (1994–1997) was over 30 % for both men and for
women. [7] In stark contrast to other cardiovascular
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diseases, the incidence and prevalence of CHF continue to
increase, for reasons including an aging population and
better treatment of coronary disease and hypertension.
Patients with heart failure create broad reaching manage-
ment issues for both primary care physicians and
specialists.
Gender differences may exist between patients with heart
failure. [8–13] Although the overall prevalence is similar,
women make up a greater percentage of patients in those
over 75 years of age.[3,4] The syndrome results from car-
diac dysfunction which is either systolic (reduced ejection
fraction and ventricular dilatation) or diastolic (impaired
myocardial relaxation leading to elevated end-diastolic
pressures with normal cardiac chamber size). Women
may have more hypertension, diabetes, and diastolic dys-
function then men, and less coronary disease. [14,15] Pre-
vious epidemiological studies such as Framingham and
the National Health and Nutrition Examination Survey re-
port better survival in women with CHF.[2,5] These stud-
ies did not assess left ventricular (LV) function, and
therefore, probably captured more women with diastolic
dysfunction, which bodes a better prognosis. More recent
studies enrolling only patients with systolic dysfunction,
have reported that women, in fact, have higher mortality
rates.[16]
The management and prognosis in heart failure patients
will vary depending on the etiology, and it is critical to as-
sess LV function and look for precipitating factors, as rec-
ommended by Canadian guidelines. [17] It is extremely
important to assess for possible gender differences in the
profile, presentation and management of patients with
heart failure to ensure optimal medical care for both men
and women, given the possible differences in pathophys-
iology and presentation of disease. Although there is a
large body of literature on "gender discrepancies" in the
management of coronary disease (CAD) [18]-[29] there is
a relative paucity of data on the evaluation of heart failure
patients and gender. One recent study found that women
with CHF are less likely to undergo assessment of LV func-
tion.[30] There is also evidence that women receive less
Angiotensin Converting Enzyme (ACE) inhibitors in the
treatment of CHF.[11,29,30]
Given the growing epidemic of CHF, it is important to
evaluate if gender differences exist in the etiology and
management of CHF. We conducted a pilot study to deter-
mine if gender differences exist in the etiology, diagnostic
work-up, or management of patients admitted to tertiary
care teaching hospital with a diagnosis of CHF.
Methods
The study took place at St. Michael's hospital, a tertiary
care teaching centre in Toronto, Canada. Consecutive pa-
tients with a primary discharge diagnosis of CHF (ICD
codes #428.0) between June 1997 and June 1998 were
identified. Patients were enrolled during their first hospi-
tal admission during the study period. Subsequent admis-
sions, if any, were not analyzed. An unbiased observer
(R.Y.) reviewed the charts and recorded predetermined
variables, if present, in the following categories: grade/eti-
ology, diagnostic investigations, and management of
CHF. (see below)
Grade/Etiology
The presence of hypertension, diabetes mellitus, previous
myocardial infarctions, and revascularization [coronary
artery bypass grafting (CABG) or percutaneous translumi-
nal coronary angioplasty (PTCA); past and present] was
noted. Coronary disease (CAD) was defined as a history of
myocardial infarction, CABG, PTCA, or chart documenta-
tion of "CAD" as assessed by the attending physician. The
ejection fraction (if documented in the patient chart) was
recorded. Previous admissions for CHF were noted. If
there was a result of an angiogram, echocardiogram, or
nuclear test, the left ventricular ejection fraction (LVEF)
was graded 1 to 4 based on the test result. [LVEF > 60% =
grade 1, LVEF 40–59% = grade 2, LVEF 20–39% = grade 3,
and LVEF 0–19% = grade 4.] Other risk factors for CHF
such as valvular heart disease, body mass index, left ven-
tricular hypertrophy, and alcohol abuse were not record-
ed, as they were not uniformly noted on charts.
Diagnostic investigations
The use of echocardiogram, multiple gated cardiac blood
pool imaging (MUGA), and/or cardiac catheterization, ei-
ther during the current admission, or comments from pre-
vious studies, was recorded. With respect to non-invasive
assessment of left ventricular function, the analysis in-
cluded current studies or previous studies as noted in the
chart.
Management
The triage of patients [medical floor vs. cardiology ward
vs. coronary care unit (CCU)/intensive care unit (ICU)]
and the use of cardiac monitors were recorded. In our in-
stitution patients are uniformly monitored in the CCU
and ICU, however, on the cardiology floor monitored
beds are at the discretion of the treating physician. The use
of ACE inhibitors, β-blockers, diuretics, and digoxin, were
recorded based on discharge medications and inpatient
medication records.
Statistical analysis
Differences between males and females were assessed us-
ing χ2 tests (Fischer's Exact Test in the case of expected cell
counts less than 5) for categorical variables and Wilcoxon
Rank Sum tests for ordinal variables. Logistic regression
analysis was used to assess the association between genderBMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/1
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and non-invasive assessment of left ventricular function.
Covariates assessed were age, presence of diabetes melli-
tus, hypertension, and coronary artery disease. In order to
assess the fit of the model, deviances from fitting the mod-
el with and without the covariate were compared. The dif-
ferences in the deviances were assumed to follow a chi-
square distribution. All analyses were done using the SPSS
and SAS® statistical packages.
Results
One hundred and fifty three patients fulfilled entry crite-
ria. Of these, 145/153 (95%) charts were available for re-
view. There were 80 male (M) patients, and 65 female (F)
patients in this group. The average age did not differ be-
tween men and women [71.6 ± 11.1 (SD) years vs. 71.3 ±
13.8 (SD) years (M vs. F), p = NS]. The range of ages for
women and men respectively was 34 to 89 and 41 to 93.
Men had worse left ventricular function than women,
[median LVEF 3 vs. 2 (M vs. F), p < 0.01]. There was no dif-
ference in the rates of previous admission to hospital for
CHF [49% M vs. 57% F)].
Gender differences in the profile and management of pa-
tients appear in Table 1. Male patients were more likely
than females to have had a previous myocardial infarction
(66% vs. 35%, p < 0.01). Male patients were more likely
to have had bypass surgery or angioplasty during this ad-
mission or previously [41% vs. 20% (M vs. F), p < 0.05].
Correspondingly, males had a higher rate of CAD than fe-
males [70% vs. 37% (M vs. F), p < 0.001]. However, there
were no gender differences seen in rates of hypertension
[58% M vs. 55%] or diabetes [40% M vs. 31% F] in this
population.
In this cohort, male patients were more likely than wom-
en to have a non-invasive (echo or nuclear) assessment of
LV function during their hospital stay [85% and 69% re-
spectively, p < 0.05]. The odds ratio (OR) and 95% Con-
fidence Interval (CI) for males was 2.53 (1.12,5.65).
Because more men than women had diagnosed coronary
artery disease, and because more patients with coronary
artery disease had a non-invasive assessment of their left
ventricular function OR (95% CI) 2.13 (0.96,4.76)], we
did an additional logistic regression analysis to assess
whether coronary artery disease (CAD) confounds the re-
lation between sex and non-invasive assessment of left
ventricular function. The addition of CAD resulted in a
model with a poorer fit than the model with sex alone.
Nevertheless there is some indication of a small con-
founding influence, since the odds ratios for both CAD
and SEX were altered towards the null value, OR (95%CI)
1.68 (0.72–3.91), 2.14 (0.91–5.01), respectively. Howev-
er, it also suggests that sex is a stronger influence on refer-
ral practice. Because more men than women had CAD, it
is not clear in this analysis whether it was the patients' sex
or the presence of CAD that influenced the physicians' de-
cisions. To further explore this we stratified by CAD status
to assess the relation between SEX and non-invasive test-
ing. Among those with CAD, sex was not related to non-
invasive testing, OR (95%CI) 1.05 (0.29–3.79), whereas
among those with no CAD, males were more likely to re-
ceive non-invasive testing, OR (95% CI) 4.48 (1.15–
17.50), suggesting that both CAD and sex are independ-
ent factors in referral practice.
Table 1: Gender differences in profile and management
Male N = 80 Female N = 65
Etiology
Previous Myocardial Infarction 66% 35% ††
Hypertension 58% 55%
Diabetes Mellitus 41% 33%
Median LVEF 3 2 ††
History of CABG or PTCA 41% 20% †††
Coronary Artery Disease 70% 37% †
Diagnostic Investigations
Echo/MUGA 85% 69% †††
Echo/MUGA (patients with CAD) 84% 83%
Echo/MUGA (patients with no CAD) 88% 61%†††
Cardiac Catheterization 25% 22%
Triage
Cardiology Ward 48% 37%
CCU/ICU 39% 32%
†Monitored Bed 59% 40% †††
†p < 0.001, †p < 0.01, ††† p < 0.005BMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/1
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Age, and a diagnosis of hypertension or diabetes did not
confound the relation between sex and non-invasive
testing.
Similar numbers of male and female patients had a cardi-
ac catheterization during this admission [25% vs. 22%
respectively)].
With respect to triage, in this cohort of patients, there were
no significant differences in the rates of admission to a
cardiology floor (48% M, 37% F) or to a CCU/ICU (39%
M, 32% F). Male patients were more likely to receive a
monitored bed (CCU/ICU or cardiology ward) (59% M,
40% F, p < 0.05). In terms of prescribed medications there
were no statistical differences in the use of ACE inhibitors,
beta-blockers, diuretics, or digoxin (see table 2). Further-
more in the subgroup of patients with grade 3 to 4 LV
function there were no differences in the use of ACE in-
hibitors, beta-blockers, or digoxin (see table 3).
Discussion
The most important finding in this study is that, among
heart failure patients with no known history of coronary
artery disease, women were less likely to be referred for
non-invasive assessment of left ventricular function. We
also found that the heart failure patients with coronary ar-
tery disease were more likely to be referred for non-inva-
sive testing.
Eighty-five percent of men as compared to 69% of women
had non-invasive assessments of LV function (via echo or
nuclear imaging). Although the men and women in this
group differed in rates of coronary disease (previous myo-
cardial infarction and revascularization), this does not ful-
ly explain the lack of assessment of female patients. In
those without coronary disease, a logistic regression anal-
ysis found men more likely to undergo non-invasive test-
ing than women. The absence of CAD should not negate
the necessity of LV assessment since the causes of CHF are
multifactorial. Therefore, the finding that men in our co-
hort had more CAD does not justify their more frequent
assessment of LV function as compared to women. Impor-
tantly women were under-evaluated, regardless of a gen-
der comparison, with only 69% having a non-invasive
assessment of LV function with an admission diagnosis of
CHF. This lack of evaluation should be highlighted since
assessment of LV function is probably the most important
diagnostic and prognostic step in evaluation of this com-
mon patient population.
Little is known on gender differences in the etiology of
CHF. In our cohort of patients with CHF, of those patients
tested, women had preserved LV function as compared to
their male counterparts. This is consistent with other re-
ports that have noted that women are more likely to have
had CHF despite having less severe LV dysfunction.
Mendes et al. [12] evaluated over one thousand, five hun-
dred patients who had undergone coronary angiography
and found that women with more symptoms of CHF were
found to have better LV function. Female patients had
smaller end-diastolic volumes, despite similar LV end-di-
astolic pressures, implicating diastolic dysfunction as the
etiology of the heart failure. These retrospective data,
along with the data from this current study, raises the
Table 2: Drug treatment in CHF patients
Medication Class Male n = 80 Female n = 65
ACE inhibitors 56(70%) 41/(63%)
Digoxin 38 (48%) 25 (38%)
B-Blockers 32 (40%) 18 (28%)
Diuretics 63 (79%) 49 (75%)
P = NS for all comparisons
Table 3: Drug treatment in CHF patients with Grade 3 or 4 LV Function
Medication Class Male n = 46 Female n = 20
ACE inhibitors 36 (78%) 15 (75%)
Digoxin 15 (33%) 10 (50%)
B-Blockers 14 (33%) 9 (45%)
P = NS for all comparisonsBMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/1
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need for ongoing evaluation of gender differences in the
etiology of heart failure.
Accounting for differences in systolic and diastolic dys-
function may be explained partly in differing underlying
causes of heart failure. This study, consistent with other
larger studies, demonstrated that men with CHF are more
likely to have had a prior myocardial infarction. Although
not seen in this study, possibly due to lack of statistical
power, others have noted gender differences in the rates of
hypertension and diabetes in heart failure patients, both
potential causes of diastolic dysfunction.[12] In both the
Framingham study and the Studies of Left Ventricular
Dysfunction (SOLVD) trial women were more likely to
have hypertension and diabetes than their male counter-
parts.[2,5,16,31] The possibility exists that there may be
myocardial properties and/or hormonal environments
unique to women contributing to heart failure. In a study
by Carroll et al examining LVH caused by aortic stenosis,
women had smaller, thicker-walled ventricles despite sim-
ilar outflow obstruction, suggesting that female ventricles
may respond differently to a pressure-overload state.[9]
Reis et al, has recently shown that women in heart failure
trials on estrogen, have a greater survival rate than those
not on hormone replacement.[32] While intriguing and
hypothesis generating, many of these studies have been
retrospective, and underscore the need for further evalua-
tion of women with heart failure, from bench to bedside.
Limited data exists on the triage and management of pa-
tients with CHF. In this particular group, there were no
gender differences noted in the triage of patients. Al-
though men were more likely to be assigned a monitored
bed, they also had a higher incidence of known coronary
disease. Men in this cohort were also more likely to have
undergone revascularization procedures; this possibly is
also explained by the higher incidence of known coronary
disease. Although not statistically significant, there was a
trend for women to be admitted to a general medical floor
as opposed to a cardiology floor or CCU. This cannot be
explained by age difference, because in contrast to other
heart failure populations, the group admitted was of sim-
ilar age. Although the literature suggests a gender bias in
the evaluation and treatment of coronary disease [33–38],
there is a paucity of data on the differences between diag-
nostic procedures in men and women with CHF. This data
is compelling evidence however for a more formal evalu-
ation of gender differences in the diagnostic work-up of
heart failure.
The last area studied in this cohort was the use of prescrip-
tion medications. Previous reports have noted underutili-
zation of ACE inhibitors in both sexes, with some reports
noting a sex disparity.[30,39] Our data showed no statis-
tical difference between prescription use of ACE inhibitors
in men and women. Although there were no differences
seen in medication use, the sample size was not large, and
there may have been differences, which were not apparent
due to lack of statistical power. Although this is consistent
with other data from Ontario[7], it is in contrast to other
preliminary data from eastern Canada[40] that show gen-
der discrepancies in the treatment of heart failure, and
therefore, raises the possibility of a regional variation in
prescribing practices.
As in any chart review, there are inherent limitations to
our study. The use of hospital charts may be limited by re-
call bias, as tests performed outside of a hospital admis-
sion, may not have been recorded on the chart. However,
it is reasonable that efforts are made to obtain this infor-
mation and convey it on the chart during an admission to
a teaching hospital. A recent assessment of LV function
would influence the need for obtaining an echocardio-
gram on a current admission. However in this pilot study,
men and women were equally as likely to have been hos-
pitalized previously for CHF, and the chart was reviewed
for such an assessment during the previous admission. It
is also possible that the use of ICD codes underestimated
the number of CHF admissions, as the institution in
which this study was conducted has several thousand ad-
missions yearly in the cardiac program. Despite these lim-
itations, this survey offers a "snap shot" of current
practices in such an institution. Lastly, although this study
may have been underpowered to detect certain differences
such as the use of ACE inhibitors, it raises important ques-
tions that must be addressed in clinical practice in the
future.
Conclusion
In summary, there have been few studies to date that have
analysed gender differences in assessment and manage-
ment of heart failure. In this cohort of patients, women
had less frequent non-invasive evaluations of left ven-
tricular function than their male counterparts. Significant-
ly, LV function is the most important prognostic marker
for patient outcome. Furthermore, a difference in non-in-
vasive evaluation has significant implications in patient
care, as the management of diastolic and systolic dysfunc-
tion varies. This pilot study was underpowered to show
gender differences in treatment such as the use of ACE in-
hibitors. A recent study by Roger et al.[41] examining sex
differences in unstable angina patients demonstrated that
female patients with unstable angina had less cardiac di-
agnostic procedures but, perhaps paradoxically, had bet-
ter long term outcomes when adjusting for baseline
characteristics. Our study also demonstrates a diagnostic
discrepancy in the work-up of patients with CHF.
Although concerning, it remains to be seen if this gender
difference translates into differences in patient outcomes.BMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/1
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This important pilot data justifies the need for larger stud-
ies to assess gender discrepancies in heart failure. It also
highlights the clinical problem of optimal evaluation and
management of women with this common condition.
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